Ingrezza

Active Ingredient(s): Valbenazine
FDA Approved: * April 11, 2017
Pharm Company: * NEUROCRINE BIOSCIENCES INC
Category: Neurological Disorders

Valbenazine, sold under the trade name Ingrezza, is a medication used to treat tardive dyskinesia.[1] It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.[2] Contents 1 Medical use 2 Contraindications 3 Adverse effects 4 Pharmacology 4.1 Mechanism of action 4.2 Pharmacokinetics 5 Society and culture 5.1 Commercial aspects 5.2 Intellectual property 5.3 Names 6 Research 7 References Medical use Valbenazine is used to treat tardive dyski... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ingrezza 40 mg Oral Capsule
NDC: 70370-1040
Labeler:
Neurocrine Biosciences, Inc.
Ingrezza Oral Kit
NDC: 70370-1048
Labeler:
Neurocrine Biosciences, Inc.
Ingrezza 60 mg Oral Capsule
NDC: 70370-1060
Labeler:
Neurocrine Biosciences, Inc.
Ingrezza 80 mg Oral Capsule
NDC: 70370-1080
Labeler:
Neurocrine Biosciences, Inc.
Ingrezza 40 mg Oral Capsule
NDC: 70370-2040
Labeler:
Neurocrine Biosciences, Inc.
IngrezzaIngrezza Oral Kit
NDC: 70370-2048
Labeler:
Neurocrine Biosciences, Inc.